Dyspnea (breathlessness) in Amyotrophic Lateral Sclerosis/motor Neuron Disease: Prevalence, Progression, Severity, and Correlates

Overview

Journal Amyotroph Lateral Scler Frontotemporal Degener

Specialty Neurology

Date 2024 Mar 11

PMID 38465877

Authors

Carolyn A Young

Amina Chaouch

Christopher J McDermott

Ammar Al-Chalabi

Suresh K Chhetri

Kevin Talbot

Timothy Harrower

Richard W Orrell

Joe Annadale

C Oliver Hanemann

Antonio Scalfari

Alan Tennant

Roger Mills

Affiliations

Soon will be listed here.

Abstract

Objective: Dyspnea, or breathlessness, is an important symptom in amyotrophic lateral sclerosis/motor neuron disease (ALS/MND). We examined the measurement properties of the Dyspnea-12.

Methods: Rasch analysis enabled conversion of raw Dyspnea-12 scores to interval level metric equivalents. Converted data were used to perform trajectory modeling; those following different trajectories were compared for demographic, clinical, symptom, and functioning characteristics. Logistic regression examined differences between distinct trajectories.

Results: In 1022 people, at baseline, mean metric Dyspnea-12 was 7.6 (SD 9.3). 49.8% had dyspnea, severe in 12.6%. Trajectory analysis over 28 months revealed three breathlessness trajectories: group 1 reported none at baseline/follow-up (42.7%); group 2 significantly increased over time (9.4%); group 3 had a much higher level at baseline which rose over follow-up (47.9%). Group 3 had worse outcomes on all symptoms, functioning and quality of life; compared to group 1, their odds of: respiratory onset sixfold greater; King's stage ≥3 2.9 greater; increased odds of being bothered by choking, head drop, fasciculations, and muscle cramps; fatigue and anxiety also elevated ( < .01).

Conclusion: Dyspnea is a cardinal symptom in ALS/MND and can be quickly measured using the Dyspnea-12. Raw scores can easily be converted to interval level measurement, for valid change scores and trajectory modeling. Dyspnea trajectories reveal different patterns, showing that clinical services must provide monitoring which is customized to individual patient need. Almost half of this large population had worsening dyspnea, confirming the importance of respiratory monitoring and interventions being integrated into routine ALS care.

References

Wilson I, Cleary P . Linking clinical variables with health-related quality of life. A conceptual model of patient outcomes. JAMA. 1995; 273(1):59-65. View

Ekstrom M, Bornefalk H, Skold C, Janson C, Blomberg A, Sandberg J . Minimal clinically important differences for Dyspnea-12 and MDP scores are similar at 2 weeks and 6 months: follow-up of a longitudinal clinical study. Eur Respir J. 2020; 57(3). DOI: 10.1183/13993003.02823-2020. View

Hagell P, Westergren A . Sample Size and Statistical Conclusions from Tests of Fit to the Rasch Model According to the Rasch Unidimensional Measurement Model (Rumm) Program in Health Outcome Measurement. J Appl Meas. 2016; 17(4):416-431. View

Bakker L, Schroder C, van Es M, Westers P, Visser-Meily J, van den Berg L . Assessment of the factorial validity and reliability of the ALSFRS-R: a revision of its measurement model. J Neurol. 2017; 264(7):1413-1420. PMC: 5502060. DOI: 10.1007/s00415-017-8538-4. View

van Eijk R, van den Berg L, Lu Y . Composite endpoint for ALS clinical trials based on patient preference: Patient-Ranked Order of Function (PROOF). J Neurol Neurosurg Psychiatry. 2021; 93(5):539-546. PMC: 9016230. DOI: 10.1136/jnnp-2021-328194. View

Simsic A, Yorke J, Regueiro E, Di Lorenzo V, Baddini-Martinez J . Validation of the dyspnoea-12 scale into Portuguese speaking COPD patients. Clin Respir J. 2018; 12(5):1942-1948. DOI: 10.1111/crj.12762. View

Gronseth R, Vollmer W, Hardie J, Olafsdottir I, Lamprecht B, Buist A . Predictors of dyspnoea prevalence: results from the BOLD study. Eur Respir J. 2013; 43(6):1610-20. PMC: 4143752. DOI: 10.1183/09031936.00036813. View

Gibbons C, Mills R, Thornton E, Ealing J, Mitchell J, Shaw P . Development of a patient reported outcome measure for fatigue in motor neurone disease: the Neurological Fatigue Index (NFI-MND). Health Qual Life Outcomes. 2011; 9:101. PMC: 3282643. DOI: 10.1186/1477-7525-9-101. View

Bausewein C, Farquhar M, Booth S, Gysels M, Higginson I . Measurement of breathlessness in advanced disease: a systematic review. Respir Med. 2006; 101(3):399-410. DOI: 10.1016/j.rmed.2006.07.003. View

10.

Helleman J, Kruitwagen-van Reenen E, Bakers J, Kruithof W, van Groenestijn A, Jaspers Focks R . Using patient-reported symptoms of dyspnea for screening reduced respiratory function in patients with motor neuron diseases. J Neurol. 2020; 267(11):3310-3318. PMC: 7578163. DOI: 10.1007/s00415-020-10003-5. View

11.

Nishimura K, Oga T, Nakayasu K, Taniguchi H, Ogawa T, Watanabe F . Comparison between tools for measuring breathlessness: Cross-sectional validation of the Japanese version of the Dyspnoea-12. Clin Respir J. 2021; 15(11):1201-1209. DOI: 10.1111/crj.13427. View

12.

Ornbjerg L, Christensen K, Tennant A, Hetland M . Validation and assessment of minimally clinically important difference of the unadjusted Health Assessment Questionnaire in a Danish cohort: uncovering ordinal bias. Scand J Rheumatol. 2019; 49(1):1-7. DOI: 10.1080/03009742.2019.1637932. View

13.

Terwee C, Peipert J, Chapman R, Lai J, Terluin B, Cella D . Minimal important change (MIC): a conceptual clarification and systematic review of MIC estimates of PROMIS measures. Qual Life Res. 2021; 30(10):2729-2754. PMC: 8481206. DOI: 10.1007/s11136-021-02925-y. View

14.

Cedarbaum J, Stambler N, Malta E, Fuller C, Hilt D, Thurmond B . The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III). J Neurol Sci. 1999; 169(1-2):13-21. DOI: 10.1016/s0022-510x(99)00210-5. View

15.

Sundh J, Bornefalk H, Skold C, Janson C, Blomberg A, Sandberg J . Clinical validation of the Swedish version of Dyspnoea-12 instrument in outpatients with cardiorespiratory disease. BMJ Open Respir Res. 2019; 6(1):e000418. PMC: 6797319. DOI: 10.1136/bmjresp-2019-000418. View

16.

Devlin N, Shah K, Feng Y, Mulhern B, van Hout B . Valuing health-related quality of life: An EQ-5D-5L value set for England. Health Econ. 2017; 27(1):7-22. PMC: 6680214. DOI: 10.1002/hec.3564. View

17.

Meyer T, Miller M, Metzger R, Borkovec T . Development and validation of the Penn State Worry Questionnaire. Behav Res Ther. 1990; 28(6):487-95. DOI: 10.1016/0005-7967(90)90135-6. View

18.

Swigris J, Yorke J, Sprunger D, Swearingen C, Pincus T, du Bois R . Assessing dyspnea and its impact on patients with connective tissue disease-related interstitial lung disease. Respir Med. 2010; 104(9):1350-5. PMC: 2914213. DOI: 10.1016/j.rmed.2010.03.027. View

19.

Franchignoni F, Mandrioli J, Giordano A, Ferro S . A further Rasch study confirms that ALSFRS-R does not conform to fundamental measurement requirements. Amyotroph Lateral Scler Frontotemporal Degener. 2015; 16(5-6):331-7. DOI: 10.3109/21678421.2015.1026829. View

20.

Parshall M, Schwartzstein R, Adams L, Banzett R, Manning H, Bourbeau J . An official American Thoracic Society statement: update on the mechanisms, assessment, and management of dyspnea. Am J Respir Crit Care Med. 2012; 185(4):435-52. PMC: 5448624. DOI: 10.1164/rccm.201111-2042ST. View